No Data
Immunobiological research shows signs of recovery, and the profit Financial Estimates for the fiscal year ending March 2025 have been revised upwards.
Immunobiological Research <4570.T> is showing a rising trend. After the close on the 18th, it was positively perceived after revising upwards the consolidated profit estimates for the fiscal year ending March 2025. In the performance forecast for the fiscal year ending March 2025, revenue is maintained at 925 million yen (a 13.4% increase from the previous term), but the operating profit was increased from 120 million yen to 180 million yen (a 73.1% increase). Revenue is expected to proceed as previously forecasted. In terms of profits, the antibody-related business features its main product, Angiotensin, which has a high profit margin.
February 19 [Today's Investment Strategy]
[Fisco Selected Stocks] 【Material Stocks】 Fusoh Chemical Industry <4368> 3500 yen (2/18) engages in ultra-high purity colloidal silica used in Food Additives such as malic acid and polishing materials for Semiconductor wafers. The performance Financial Estimates for the fiscal year ending March 2025 have been revised upward. The operating profit is expected to be 160 yen (an increase of 44.3% compared to the previous term). This is an increase of about 18% from the previous estimate. Sales for the Semiconductor market are strong. The effects of the weak yen are also contributing. The year-end Dividends are set at 38 yen. The previous estimate was 35 yen, and the year-end of the previous term.
Focus on Fusso Chemicals and Konishi, the trends ETC seem to be weak.
In the US stock market yesterday, on the 18th, the Dow Jones Industrial Average rose by $10.26 to 44,556.34, the Nasdaq Composite Index increased by 14.49 points to 20,041.26, and the Chicago Nikkei 225 Futures were up by 10 yen compared to the Osaka daytime, reaching 39,300 yen. The exchange rate is 1 dollar = 152.00-10 yen. In today's Tokyo market, Fusoh Chemicals <4368> announced an upward revision of the financial estimates and dividends for the fiscal year ending March 2025, reporting a special profit from the sale of investment securities amounting to 0.397 billion yen and implementing a 5.0 yen commemorative dividend for the 100th anniversary.
Immunobiology Research Institute, Genepha, etc.
＜3195＞ Obtained a patent for filling materials containing Genepacapok fibers and feathers and their manufacturing devices and methods. <3558> Changed the Jade Group Shareholder benefit program. <3905> Issuance of the 20th subscription rights by Data Section (with exercise price adjustment provisions, potential number of stocks is 4.4 million shares, raising approximately 3.024 billion yen). <3967> Recorded a special profit of 0.015 billion yen from the sale of investment securities by Eltes. <4058> Completed the acquisition of treasury shares by Toyokumo. <4570> Immunobiological Research Institute.
Fusang Chemicals, upward revision as of March 25, operating profit 16 billion yen, previously 13.5 billion yen.
Fusang Chemicals <4368> announced a revision of its Financial Estimates for the fiscal year ending March 2025. Revenue has been revised upward from 68 billion yen to 69.4 billion yen, and operating profit has been adjusted from 13.5 billion yen to 16 billion yen. Sales for the Semiconductors market have been performing well. Additionally, due to the Exchange Rates moving more favorably than anticipated towards a weaker yen, both revenue and operating profit have increased. Regarding the year-end Dividends forecast, it has been raised by 3 yen per share from the previous estimate to 38 yen. The total annual Dividends, including the interim Dividends of 35 yen, will be 73 yen per share.
Key points of interest in the PTS on the 18th = Fusosha Chemicals, Genepar, and Izu Shabote ETC.
▽ Fuson Chemicals <4368.T> has revised upward its consolidated operating profit Financial Estimates for the fiscal year ending March 2025 from 13.5 billion yen to 16 billion yen (an increase of 44.4% compared to the previous period). Annual Dividends are projected to be 73 yen (previously estimated at 70 yen, with the last year being 66 yen). ▽ Genepa <3195.T> has acquired a patent for filling materials made from a blend of kapok fiber and down feathers, along with the corresponding manufacturing equipment and methods. ▽ Izu Shabote <6819.T> has revised its Dividends forecast and changed its Shareholder benefit program. ▽ Immuno Biological Research <4570>